MTN-038

A Phase I study of a 90-day vaginal ring containing tenofovir that was developed to protect women against both HIV and herpes simplex virus type 2 (HSV-2). The study assessed the safety of the ring and drug levels in tissue among 49 women at three U.S. trial sites. Results are anticipated in mid to late 2020.

 

MTN researchers begin safety study of a 90-day vaginal ring containing tenofovir

2019-Jan-16

 

See Also

MTN-038 Protocol

 

MTN-038 Study Page


Source URL: https://mtnstopshiv.org/news/studies/mtn038